John Libbey Eurotext

Hématologie

MENU

Pathophysiology and abnormalities of hemostasis in intensive care patients with Covid-19 Volume 27, issue 1, Janvier-Février 2021

Figures

  • Figure 1

Tables

Authors
1 Service d’hématologie biologique, hôpital Lariboisière, AP-HP.Nord, université de Paris, Paris, France
2 EA3518, Recherche clinique en hématologie, immunologie et transplantation, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
3 UMR-S1140 Inserm, thérapies innovantes en hémostase, université de Paris, Paris, France
* Tirés à part

Coronavirus disease 2019 (Covid-19), a severe acute respiratory syndrome caused by coronavirus 2 (Sars-CoV-2), has now spread to all continents. About 5-10 % of Covid-19 patients require intensive care unit admission and mechanical ventilation. Critically ill Covid-19 patients are prone to develop hypoxia, excessive inflammation and frequent thrombotic manifestations affecting both the macrocirculation and the microcirculation.